Retrophin, Inc. logo

Retrophin, Inc.

Retrophin is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases. Retrophin (NASDAQ:RTRX) is a fully-integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”RTRX” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.retrophin.com
Founded2011
Disease Focus
Development Stage
STOCK CODENASDAQ: RTRX
Address
3721 Valley Centre Drive, Suite 200, CA, 92130
San Diego
United States
Email
Contact Number
+1 760-260-8600

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/retrophin” connections=”true” suffix=””]

In Oct. 2014, Retrophin, divest non-core assets ketamine, Syntocinon Nasal Sprayë (oxytocin), and Vecamylë (mecamylamine HCI tablets) to Turing Pharmaceuticals for a $3 Mn upfront payment. Turning is developing intranasal formulation of ketamine for a variety of psychiatric indications.